Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: Relation to clinical manifestations and disease activity

Joint Bone Spine

Volumn 79, Issue 3, 2012, Pages 285-290

  Gheita, Tamer A ^a   Bassyouni, Iman H ^a   Emad, Yasser ^a   El Din, Abeer M Nour ^b   Abdel Rasheed, Enas ^b   Hussein, Hani ^c  

^a Cairo University   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

APRIL; BAFF; Juvenile idiopathic arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CORTICOSTEROID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR;

ADOLESCENT; ANTIBODY TITER; ARTHRITIS; ARTICLE; CHILD; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; POLYARTHRITIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEROLOGY; SERUM; TREATMENT INDICATION; UVEITIS;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH STATUS; HUMANS; MALE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UVEITIS;

EID: 84860596182     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.05.020     Document Type: Article

References (27)

1. Quartier P. Current treatments for juvenile idiopathic arthritis. Joint Bone Spine 2010, 77:511-516.
2. Martini A., Lovell D.J. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 2010, 69:1260-1263.
3. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237:264-283.
4. Mackay F., Sierro F., Grey S.T., et al. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005, 8:243-265.
5. Le Pottier L., Bendaoud B., Renaudineau Y., et al. New ELISA for B cell-activating factor. Clin Chem 2009, 55:1843-1851.
6. Krivosikova M., Dallos T., Maslinski W., et al. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases. Bratisl Lek Listy 2009, 110:137-145.
7. Becker-Merok A., Nikolaisen C., Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006, 15:570-576.
8. Gottenberg J.E., Miceli-Richard C., Ducot B., et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009, 11:R114.
9. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
10. Moura R.A., Cascão R., Perpétuo I., et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology 2011, 50:278-282.
11. Bosello S., Youinou P., Daridon C., et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008, 35:1256-1264.
12. Benucci M., Manfredi M., Puttini P.S., et al. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmun Rev 2010, 9:801-803.
13. Hong S.D., Reiff A., Yang H.T., et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum 2009, 60:3400-3409.
14. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
15. Consolaro A., Ruperto N., Bazso A., et al. Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009, 61:658-666.
16. Singh G., Athreya B.H., Fries J.F., et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761-1769.
17. Bassyouni I.H., Azab N., El-Dakrony E., et al. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis?. Joint Bone Spine 2011, 78:56-61.
18. Wouters C.H., Ceuppens J.L., Stevens E.A. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002, 20:239-248.
19. Jansson A.F., Sengler C., Kuemmerle-Deschner J., et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 2011, 30:87-97.
20. Kuek A., Hazleman B.L., Gaston J.H., et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology 2006, 45:1448-1449.
21. Feito J.G., Pereda C.A. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 2009, 15:363-365.
22. Kasher-Meron M., Uziel Y., Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report. Rheumatology 2009, 48:445-446.
23. Looney R.J. B cell-targeted therapy in diseases other than rheumatoid arthritis. J Rheumatol Suppl 2005, 73:25-28.
24. Qian Y., Acharya N.R. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 2010, 21:468-472.
25. Parikh J.G., Tawansy K.A., Rao N.A. Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 2008, 115:1833-1836.
26. Amer R., Bamonte G., Forrester J.V. Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency. Eur J Ophthalmol 2007, 17:666-668.
27. Tappeiner C., Heinz C., Specker C., et al. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007, 39:184-186.